Bladder cancer marker shows promises in study
This article was originally published in Clinica
Executive Summary
A screening test based on a new urinary marker for bladder cancer has been found to have a sensitivity of 100% in preliminary trials. Yale University in New Haven, Connecticut, has filed a US patent application covering a method for detecting the marker, the naturally occurring apoptosis inhibitor survivin. Survivin is over-expressed in common cancers.